AllAnalyst Report
logoArgusSeptember 20, 2022

Bio-Techne Corporation: Reaffirming BUY

Symbols
TECH
Sector(s)
Healthcare
Rating
Current Price
$63.69
Price Target
Earnings Estimate
Summary

Based in Minneapolis, Bio-Techne develops and markets protein-based instruments and reagents for pharmaceutical and biotech research and clinical use. Its customers include companies in the pharmaceutical and biotech industries as well as academic research institutions. The company's products and solutions aid in drug discovery and provide the means for accurate clinical tests and diagnoses. Through its Protein Sciences business segment, Bio-Techne is one of the world's leading suppliers of proteins, such as cytokines and growth factors, immunoassays, antibodies, and reagents to the biotech and academic research communities. Bio-

Upgrade to begin using premium research reports and get so much more.

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Upgrade

Analyst Profile

David H. Toung

Senior Analyst: Medical Devices & Healthcare Services
David covers the Pharmaceutical, Medical Devices, and Healthcare services sectors for Argus. He has more than two decades of experience in the financial analysis industry, having worked for McDonald & Co., JPMorgan Chase and Standard & Poor's, among others. His commentary has appeared on CNBC and in The New York Times. Prior to his financial career, David was a private practice attorney in New Jersey, and served as a Judicial Clerk for an Appellate Division judge in the New Jersey Superior Court. David has a law degree from Rutgers University, where he was a member of the Law Review. He has a B.A. degree in Government from Cornell University. He has passed Level II of the Chartered Financial Analyst examination.